Drug Profile
Research programme: breast cancer gene therapy - Copernicus Therapeutics
Latest Information Update: 25 Mar 2008
Price :
$50
*
At a glance
- Originator Copernicus Therapeutics
- Developer Case Western Reserve University; National Cancer Institute (USA)
- Class Antineoplastics; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 25 Mar 2008 Discontinued - Preclinical for Breast cancer in USA (unspecified route)
- 07 Dec 2006 Preclinical development is still ongoing
- 01 Aug 2002 This programme is still in active development